嵌合抗原受体
T细胞
人类免疫缺陷病毒(HIV)
免疫疗法
免疫学
抗原
T细胞受体
免疫系统
细胞毒性T细胞
遗传增强
癌症研究
病毒载体
作者
Oscar Alfageme-Abello,Raphaël Porret,Matthieu Perreau,Laurent Perez,Yannick D. Muller
出处
期刊:Current Opinion in Hiv and Aids
[Ovid Technologies (Wolters Kluwer)]
日期:2021-03-01
卷期号:16 (2): 88-97
被引量:1
标识
DOI:10.1097/coh.0000000000000665
摘要
PURPOSE OF REVIEW Cell-based immunotherapies have made enormous progress over the last decade with the approval of several anti-CD19-chimeric antigen receptor (CAR)-T cell therapies for haemato-oncological diseases. CARs are synthetic receptors comprising an antigen-specific extracellular domain fused to a hinge, transmembrane and intracellular signalling domains. The success obtained with CD19 CAR-T cells rekindled interest in using CAR-T cells to treat HIV seropositive patients. The purpose of this review is to discuss historical and recent developments of anti-HIV CARs. RECENT FINDINGS Since the first description of CD4+-based CARs in the early 90s, new generations of anti-HIV CARs were developed. They target the hetero-trimeric glycoprotein gp120/gp41 and consist of either a CD4+ extracellular domain or a VH/VL segment derived from broadly neutralizing antibodies. Recent efforts were employed in multiplexing CAR specificities, intracellular signalling domains and T cells resistance to HIV. SUMMARY Several new-anti HIV CAR-T cells were successfully tested in preclinical mice models and are now waiting to be evaluated in clinical trials. One of the key parameters to successfully using CAR-T cells in HIV treatment will depend on their capacity to control the HIV reservoir without causing off-targeting activities.
科研通智能强力驱动
Strongly Powered by AbleSci AI